From Meilssa Burroughs <[email protected]>
Subject Sign the People's Brief to Protect Mifepristone & Access to Medication
Date April 13, 2023 6:16 PM
  Links have been removed from this email. Learn more in the FAQ.
  Links have been removed from this email. Learn more in the FAQ.
Families USA logo and brand blue ribbon beneath it. [[link removed]]
Sign the People's Brief to Protect Mifepristone and Access to Medication
Partners,
As health advocates who understand that banning Mifepristone would have drastic health implications, we calling on all our partners and people across the country to join the People's Brief to Protect Mifepristone and Access to Medication. [[link removed]]
As you know, the recent ruling in Alliance for Hippocratic Medicine vs. FDA blocks the FDA's approval of one of the safest drugs on the market, mifepristone . If the ruling is upheld many more medications may be called into question, putting just about every drug in our medicine cabinets at risk.
Sign the People's Brief [[link removed]]
The People's Brief [[link removed]] is a nation-wide effort led by a coalition of stakeholder groups to show just how many people are outraged by this decision, and ensure we are on record once this case reaches the supreme court.
We hope you will join the staff at Families USA and people across the country in urging the courts to reverse this decision and uphold the law. Note that this opportunity is for individuals (rather than organizations) to sign on.
Best,
Melissa Burroughs
Director of Strategic Partnerships
Families USA
Copyright © 2022 Families USA, All rights reserved.
Our mailing address is:
Families USA
1225 New York Ave NW
Suite 800
Washington, DC xxxxxx
United States
If you believe you received this message in error or wish to no longer receive email from us, please unsubscribe: [link removed] .
Screenshot of the email generated on import

Message Analysis

  • Sender: Families USA
  • Political Party: n/a
  • Country: United States
  • State/Locality: n/a
  • Office: n/a
  • Email Providers:
    • EveryAction